The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014)

Infectious Diseases of Poverty

Volumn 5, Issue 1, 2016, Pages

  Turner, Hugo C ^a,b   Bettis, Alison A ^a,b   Chu, Brian K ^c   McFarland, Deborah A ^d   Hooper, Pamela J ^c   Ottesen, Eric A ^c   Bradley, Mark H ^e  

^a London Centre for Neglected Tropical Disease Research   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Task Force for Global Health   (United States)

^d EMORY UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

DALYs averted; Economic impact; GPELF; Health impact; Lymphatic filariasis; Programme evaluation

Indexed keywords

ALBENDAZOLE; AMOXICILLIN; IBUPROFEN; IVERMECTIN; PARACETAMOL;

AGRICULTURAL WORKER; ARTICLE; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH IMPACT ASSESSMENT; HUMAN; HYDROCELE; INFECTION RISK; LYMPHANGITIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; POPULATION RISK; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SCABIES; SENSITIVITY ANALYSIS; CHRONIC DISEASE; COST; DISABLED PERSON; ECONOMICS; ELEPHANTIASIS, FILARIAL; HEALTH; NEGLECTED DISEASES; PARASITOLOGY; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; THEORETICAL MODEL;

CHRONIC DISEASE; COSTS AND COST ANALYSIS; DISABLED PERSONS; ELEPHANTIASIS, FILARIAL; GLOBAL HEALTH; HUMANS; MODELS, THEORETICAL; NEGLECTED DISEASES; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS;

EID: 85011792310     PISSN: None     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/s40249-016-0147-4     Document Type: Article

References (93)

1. Ottesen EA. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol. 2006;61:395-441.
2. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis. 2008;2(10):e317.
3. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM. Tropical diseases targeted for elimination: chagas disease, lymphatic dilariasis, onchocerciasis, and leprosy. In: Jamison DT, Breman JG, Measham AR, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. p. 433-49.
4. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis. 2010;4(6):e708.
5. World Health Organization. PCT databank: Lymphatic filariasis [ http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/ ].
6. World Health Organization. 489 Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec. 2015;90(38):489-504.
7. Michael E, Bundy DA, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996;112(Pt 4):409-28.
8. Ramaiah KD, Ramu K, Kumar KN, Guyatt H. Epidemiology of acute filarial episodes caused by Wuchereria bancrofti infection in two rural villages in Tamil, Nadu, south India. Trans R Soc Trop Med Hyg. 1996;90(6):639-43.
9. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S. The economic burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol. 1996;90(1):39-48.
10. Pani SP, Yuvaraj J, Vanamail P, Dhanda V, Michael E, Grenfell BT, Bundy DA. Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg. 1995;89(1):72-4.
11. Krishnamoorthy K. Estimated costs of acute adenolymphangitis to patients with chronic manifestations of bancroftian filariasis in India. Indian J Public Health. 1999;43(2):58-63.
12. Ramaiah KD, Radhamani MP, John KR, Evans DB, Guyatt H, Joseph A, Datta M, Vanamail P. The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study. Ann Trop Med Parasitol. 2000;94(4):353-64.
13. Babu BV, Nayak AN, Dhal K. Epidemiology of episodic adenolymphangitis: a longitudinal prospective surveillance among a rural community endemic for bancroftian filariasis in coastal Orissa, India. BMC Public Health. 2005;5:50.
14. Gyapong JO, Gyapong M, Adjei S. The epidemiology of acute adenolymphangitis due to lymphatic filariasis in northern Ghana. Am J Trop Med Hyg. 1996;54(6):591-5.
15. Kessel JF. Disabling effects and control of filariasis. Am J Trop Med Hyg. 1957;6(3):402-14. discussion, 415.
16. Gasarasi DB, Premji ZG, Mujinja PG, Mpembeni R. Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. Acta Trop. 2000;75(1):19-28.
17. Sabesan S, Krishnamoorthy K, Pani SP, Panicker KN. Mandays lost dueto repeated attacks of lymphatic filariasis. Trends in Life Sciences. 1992;7:5-7.
18. Hooper PJ, Chu BK, Mikhailov A, Ottesen EA, Bradley M. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. PLoS Negl Trop Dis. 2014;8(11):e3333.
19. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet. 2006;367(9515):992-9.
20. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med. 2002;347(23):1841-8.
21. Bockarie MJ, Ibam E, Alexander ND, Hyun P, Dimber Z, Bockarie F, Alpers MP, Kazura JW. Towards eliminating lymphatic filariasis in Papua New Guinea: impact of annual single-dose mass treatment on transmission of Wuchereria bancrofti in East Sepik Province. P N G Med J. 2000;43(3-4):172-82.
22. Das PK, Ramaiah KD, Vanamail P, Pani SP, Yuvaraj J, Balarajan K, Bundy DA. Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans R Soc Trop Med Hyg. 2001;95(3):336-41.
23. Kimura E, Spears GF, Singh KI, Samarawickrema WA, Penaia L, Sone PF, Pelenatu S, Faaiuaso ST, Self LS, Dazo BC. Long-term efficacy of single-dose mass treatment with diethylcarbamazine citrate against diurnally subperiodic Wuchereria bancrofti: eight years' experience in Samoa. Bull World Health Organ. 1992;70(6):769-76.
24. Richards Jr FO, Pam DD, Kal A, Gerlong GY, Onyeka J, Sambo Y, Danboyi J, Ibrahim B, Terranella A, Kumbak D, et al. Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria. Ann Trop Med Parasitol. 2005;99(2):155-64.
25. Grady CA, de Rochars MB, Direny AN, Orelus JN, Wendt J, Radday J, Mathieu E, Roberts JM, Streit TG, Addiss DG, et al. Endpoints for lymphatic filariasis programs. Emerg Infect Dis. 2007;13(4):608-10.
26. Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, Padma S. Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Ann Trop Med Parasitol. 2009;103(3):235-47.
27. Partono F, Maizels RM. Purnomo: towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. Trans R Soc Trop Med Hyg. 1989;83(6):821-6.
28. Casley-Smith JR, Jamal S, Casley-Smith J. Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC). Ann Trop Med Parasitol. 1993;87(3):247-58.
29. Tisch DJ, Alexander ND, Kiniboro B, Dagoro H, Siba PM, Bockarie MJ, Alpers MP, Kazura JW. Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. PLoS Negl Trop Dis. 2011;5(7):e1241.
30. Partono F, Purnomo, Oemijati S, Soewarta A. The long term effects of repeated diethylcarbamazine administration with special reference to microfilaraemia and elephantiasis. Acta Trop. 1981;38(3):217-25.
31. Partono F. Treatment of elephantiasis in a community with timorian filariasis. Trans R Soc Trop Med Hyg. 1985;79(1):44-6.
32. Meyrowitsch DW, Simonsen PE, Makunde WH. Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of a low monthly dose and medicated salt. Trans R Soc Trop Med Hyg. 1996;90(1):74-9.
33. Ciferri F, Siliga N, Long G, Kessel JF. A filariasis-control program in American Samoa. Am J Trop Med Hyg. 1969;18(3):369-78.
34. Mackenzie CD, Lazarus WM, Mwakitalu ME, Mwingira U, Malecela MN. Lymphatic filariasis: patients and the global elimination programme. Ann Trop Med Parasitol. 2009;103 Suppl 1:S41-51.
35. March HN, Laigret J, Kessel JF, Bambridge B. Reduction in the prevalence of clinical filariasis in Tahiti following adoption of a control program. Am J Trop Med Hyg. 1960;9:180-4.
36. Fan PC, Peng HW, Chen CC. Follow-up investigations on clinical manifestations after filariasis eradication by diethylcarbamazine medicated common salt on Kinmen (Quemoy) Islands, Republic of China. J Trop Med Hyg. 1995;98(6):461-4.
37. Das L, Subramanyam Reddy G, Pani S. Some observations on the effect of Daflon (micronized purified flavonoid fraction of Rutaceae aurantiae) in bancroftian filarial lymphoedema. Filaria J. 2003;2(1):5.
38. Health Nutrition and Population Statistics. [ http://datatopics.worldbank.org/hnp/ ].
39. Global Health Observatory data repository. [ http://apps.who.int/gho/data/view.main.60280?lang=en ].
40. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-43.
41. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
42. Boccuzzi S: Indirect Health Care Costs. In: Cardiovascular Health Care Economics. Edited by Weintraub W. Totowa, NJ: Humana Press; 2003: 63-79.
43. Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J. 2007;6:2.
44. Nanda B, Krishnamoorthy K. Treatment seeking behaviour and costs due to acute and chronic forms of lymphatic filariasis in urban areas in south India. Trop Med Int Health. 2003;8(1):56-9.
45. Ramaiah KD, Guyatt H, Ramu K, Vanamail P, Pani SP, Das PK. Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Trop Med Int Health. 1999;4(1):19-25.
46. Babu BV, Nayak AN, Dhal K, Acharya AS, Jangid PK, Mallick G. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Trop. 2002;82(1):31-8.
47. Management Sciences for Health. International Drug price Indicator Guide. [ http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=English ].
48. Health Action International. Database of medicine prices, availability, affordability and price components. [ http://www.haiweb.org/MedPriceDatabase/ ].
49. Cost effectiveness and strategic planning (WHO-CHOICE). Health service delivery costs. [ http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/ ].
50. Ramaiah KD, Das PK, Michael E, Guyatt H. The economic burden of lymphatic filariasis in India. Parasitol Today. 2000;16(6):251-3.
51. Wesisbrod BA. The valuation of human capital. J Polit Econ. 1961;69:425-36.
52. Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565-73.
53. International Labour Organization's LABORSTA database, http://laborsta.ilo.org/ ].
54. World Development Indicators. [ http://data.worldbank.org/data-catalog/world-development-indicators ].
55. International Labour Organization's Minimum Wages Database. [ http://www.ilo.org/ilostat ].
56. United States Department of State Country Reports on Human Rights Practices. [ http://www.state.gov/j/drl/rls/hrrpt/ ].
57. International Monetary Fund. [ https://www.imf.org/external/pubs/ft/weo/2015/01/weodata/weoselgr.aspx ].
58. Historical Exchange Rates. [ http://www.oanda.com/currency/historical-rates/ ].
59. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
60. Keating J, Yukich JO, Mollenkopf S, Tediosi F. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop. 2014;135:86-95.
61. de Vlas SJ, Stolk WA, le Rutte EA, Hontelez JAC, Bakker R, Blok DJ, Cai R, Houweling TAJ, Kulik MC, Lenk EJ, et al. Concerted efforts to control or eliminate neglected tropical diseases: how much health will be gained? PLoS Negl Trop Dis. 2016;10(2):e0004386.
62. Accelerating work to overcome the global impact of neglected tropical diseases - A roadmap for implementation. [ http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf ].
63. Onwujekwe O, Chima R, Okonkwo P. Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endemic Nigerian communities. Health Policy. 2000;54(2):143-59.
64. Frick KD, Basilion EV, Hanson CL, Colchero MA. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol. 2003;10(2):121-32.
65. McFarland D, Menzies N, Njoumemi Z, Onwujekwe O. Study of cost per treatment with ivermectin using the CDTI strategy. African Programme for Onchocerciasis Control (APOC). 2005.
66. Muhondwa EPY. Community participation in filariasis control: the Tanzania experiment. Geneva: World Health Organization Special Programme for Research and Training in Tropical Diseases; 1983.
67. Rao CK, Sharma SP. Control of filariasis in India. J Commun Dis. 1986;18(4):276-82.
68. Ramu K, Ramaiah KD, Guyatt H, Evans D. Impact of lymphatic filariasis on the productivity of male weavers in a south Indian village. Trans R Soc Trop Med Hyg. 1996;90(6):669-70.
69. Ton TG, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. Infect Dis Poverty. 2015;4:34.
70. Ramaiah KD, Vijay Kumar KN. Effect of lymphatic filariasis on school children. Acta Trop. 2000;76(2):197-9.
71. King CH. Health metrics for helminth infections. Acta Trop. 2015;141(Pt B):150-60.
72. Knopp S, Mohammed KA, Speich B, Hattendorf J, Khamis IS, Khamis AN, Stothard JR, Rollinson D, Marti H, Utzinger J. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis. 2010;51(12):1420-8.
73. Truscott JE, Turner HC, Anderson RM. What impact will the achievement of the current World Health Organisation targets for anthelmintic treatment coverage in children have on the intensity of soil transmitted helminth infections? Parasit Vectors. 2015;8(1):551.
74. Turner HC, Truscott JE, Hollingsworth TD, Bettis AA, Brooker SJ, Anderson RM. Analysis of the population-level impact of co-administering ivermectin with albendazole or mebendazole for the control and elimination of Trichuris trichiura. Infect Dis Poverty. 2016; In press.
75. Turner HC, Truscott JE, Bettis AA, Shuford KV, Dunn JC, Hollingsworth TD, Brooker SJ, Anderson RM. An economic evaluation of expanding hookworm control strategies to target the whole community. Parasit Vectors. 2015;8:570.
76. Pion SD, Chesnais CB, Bopda J, Louya F, Fischer PU, Majewski AC, Weil GJ, Boussinesq M, Missamou F. The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the republic of congo. Am J Trop Med Hyg. 2015;92(5):959-66.
77. Heukelbach J, Winter B, Wilcke T, Muehlen M, Albrecht S, de Oliveira FA, Kerr-Pontes LR, Liesenfeld O, Feldmeier H. Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Health Organ. 2004;82(8):563-71.
78. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, Montgomery J, Pandeya N, Purdie D. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ. 2005;83(1):34-42.
79. Boatin BA, Richards Jr FO. Control of onchocerciasis. Adv Parasitol. 2006;61:349-94.
80. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014;8(11):e3319.
81. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, Vanamail P, Michael E, Das PK, Bundy DA. EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect. 2000;124(3):529-41.
82. Stolk WA, de Vlas SJ, Borsboom GJ, Habbema JD. LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology. 2008;135(13):1583-98.
83. Irvine M, Reimer L, Njenga S, Gunawardena S, Kelly-Hope L, Bockarie M, Hollingsworth T. Modelling strategies to break transmission of lymphatic filariasis - aggregation, adherence and vector competence greatly alter elimination. Parasit Vectors. 2015;8(1):547.
84. Turner HC, Walker M, French MD, Blake IM, Churcher TS, Basáñez MG. Neglected tools for neglected diseases: mathematical models in economic evaluations. Trends Parasitol. 2014;30(12):562-70.
85. Bockarie MJ, Molyneux DH. The end of lymphatic filariasis? BMJ. 2009;338:b1686.
86. van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69 Suppl 1:i89-91.
87. Ramaiah KD, Ramu K, Guyatt H, Kumar KN, Pani SP. Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop Med Int Health. 1998;3(2):108-15.
88. O'Lorcain P, Holland CV. The public health importance of Ascaris lumbricoides. Parasitology. 2000;121(Suppl):S51-71.
89. Adams EJ, Stephenson LS, Latham MC, Kinoti SN. Physical activity and growth of Kenyan school children with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved after treatment with albendazole. J Nutr. 1994;124(8):1199-206.
90. Stephenson LS, Latham MC, Adams EJ, Kinoti SN, Pertet A. Physical fitness, growth and appetite of Kenyan school boys with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved four months after a single dose of albendazole. J Nutr. 1993;123(6):1036-46.
91. Nokes C, Grantham-McGregor SM, Sawyer AW, Cooper ES, Robinson BA, Bundy DA. Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children. Parasitology. 1992;104(Pt 3):539-47.
92. Crompton DW. The public health importance of hookworm disease. Parasitology. 2000;121(Suppl):S39-50.
93. Christian P, Khatry SK, West Jr KP. Antenatal anthelmintic treatment, birthweight, and infant survival in rural Nepal. Lancet. 2004;364(9438):981-3.